Canadian Imperial Bank of Commerce
CM
Bank of Montreal
BMO
The Toronto-Dominion Bank
TD
Bank of Nova Scotia
BNS
Royal Bank of Canada
RY
NervGen Pharma Corp principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291, and NVG-300.